Katzenschlager, R., Head, J., Schrag, A., Ben-Shlomo, Y., Evans, A., Lees, A.J. and Parkinson’s Disease Research Group of the United Kingdom (2008) Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Initial Treatments in PD. Neurology, 71, 474-480.
https://doi.org/10.1212/01.wnl.0000310812.43352.66

has been cited by the following article:

• TITLE: Problems Associated with Non-Ergot Dopamine Agonist Maintenance Therapy in Patients with Advanced Parkinson’s Disease

  AUTHORS: Makoto Shiraishi, Futaba Maki, Naoshi Sasaki, Yasuhiro Hasegawa

  KEYWORDS: Parkinson’s Disease, Non-Ergot Dopamine Agonist, Wearing-Off, Ropinirole, Pramipexole

  JOURNAL NAME: Advances in Parkinson's Disease, Vol.8 No.3, August 27, 2019

  ABSTRACT: Non-ergot dopamine agonists have become popular for treating motor complications associated with long-term use of levodopa-containing drugs. We conducted a retrospective study in which we identified clinical problems related to use of non-ergot dopamine agonists. The study included 38 patients with Parkinson’s disease (PD) who suffered the wearing-off phenomenon and had thus been under non-ergot dopamine receptor agonist therapy for 1 - 2 years. Some presented with problems such as major symptoms of PD (30.3%), psychiatric symptoms (24.2%), and postural dysfunction (21.2%). Comparison between two different non-ergot drugs showed the levodopa dosage to be greater among patients taking ropinirole than among those taking pramipexole. In patients with advanced PD, various problematic symptoms can develop early after administration of a non-ergot dopamine agonist to treat the wearing-off phenomenon, necessitating identification and treatment of such symptoms on a patient-to-patient basis.